Form 4: Immunic Inc. Director Barclay A. Phillips Acquires Stock Options
SEC Form 4 Filing
Director Barclay A. Phillips acquired stock options in Immunic, Inc. on June 11, 2024.
Summary
- On June 11, 2024, Barclay A. Phillips, a director of Immunic, Inc. (IMUX), acquired 100,000 stock options.
- The exercise price of these options is $1.27.
- The options vest monthly over one year from the grant date and expire on June 11, 2034.
- Following the transaction, Phillips directly owns 100,000 derivative securities.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing indicating a director's acquisition of stock options, which can be seen as a positive sign of confidence, but it doesn't provide enough information to strongly influence sentiment.
Positives
- The acquisition of stock options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership of securities. It's common for directors and officers of publicly traded companies to receive stock options as part of their compensation.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/11/2024 | Date of earliest transaction: Barclay Phillips acquired stock options. |
| 06/11/2024 | Grant date of the stock options. |
| 06/11/2034 | Expiration date of the stock options. |
| 06/12/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.